Premium
Proline dehydrogenase (oxidase) in cancer
Author(s) -
Liu Wei,
Phang James M.
Publication year - 2012
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.1036
Subject(s) - proline dehydrogenase , biochemistry , biology , carcinogenesis , proline , transcription factor , mitochondrion , citric acid cycle , enzyme , amino acid , gene
Proline dehydrogenase (oxidase, PRODH/POX), the first enzyme in the proline degradative pathway, plays a special role in tumorigenesis and tumor development. Proline metabolism catalyzed by PRODH/POX is closely linked with the tricarboxylic acid (TCA) cycle and urea cycle. The proline cycle formed by the interconversion of proline and Δ 1 ‐pyrroline‐5‐carboxylate (P5C) between mitochondria and cytosol interlocks with pentose phosphate pathway. Importantly, by catalyzing proline to P5C, PRODH/POX donates electrons into the electron transport chain to generate ROS or ATP. In earlier studies, we found that PRODH/POX functions as a tumor suppressor to initiate apoptosis, inhibit tumor growth, and block the cell cycle, all by ROS signaling. It also suppresses hypoxia inducible factor signaling by increasing α‐ketoglutarate. During tumor progression, PRODH/POX is under the control of various tumor‐associated factors, such as tumor suppressor p53, inflammatory factor peroxisome proliferator‐activated receptor gamma (PPARγ), onco‐miRNA miR‐23b*, and oncogenic transcription factor c‐MYC. Recent studies revealed the two‐sided features of PRODH/POX‐mediated regulation. Under metabolic stress such as oxygen and glucose deprivation, PRODH/POX can be induced to serve as a tumor survival factor through ATP production or ROS‐induced autophagy. The paradoxical roles of PRODH/POX can be understood considering the temporal and spatial context of the tumor. Further studies will provide additional insights into this protein and on its metabolic effects in tumors, which may lead to new therapeutic strategies. © 2012 International Union of Biochemistry and Molecular Biology, Inc.